title: Adoptive therapy with CAR redirected T cells: the challenges in targeting solid tumors.
abstract: Recent spectacular success in the adoptive cell therapy of leukemia and lymphoma with chimeric antigen receptor (CAR)-modified T cells raised the expectations that this therapy may be efficacious in a wide range of cancer entities. The expectations are based on the predefined specificity of CAR T cells by an antibody-derived binding domain that acts independently of the natural T-cell receptor, recognizes targets independently of presentation by the major histocompatibility complex and allows targeting toward virtually any cell surface antigen. We here discuss that targeting CAR T cells toward solid tumors faces certain circumstances critical for the therapeutic success. Targeting tumor stroma and taking advantage of TRUCK cells, in other words, CAR T cells with inducible release of a transgenic payload, are some strategies envisaged to overcome current limitations in the near future.
authors.affiliation: Clinic I Internal Medicine, Tumor Genetics, University Hospital Cologne, Cologne, Germany.|Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Robert-Koch-Str. 21, D-50931 Cologne, Germany.
authors.forename: Hinrich
authors.initials: H
authors.lastname: Abken
mesh_terms: D006801:Humans; D007938:Leukemia / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D008223:Lymphoma / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D011948:Receptors, Antigen, T-Cell / Q000235:genetics / Q000276:immunology*; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology* / Q000473:pathology / Q000637:transplantation*
chemical_list: D011948:Receptors, Antigen, T-Cell; D011993:Recombinant Fusion Proteins
keywords: CAR; T cell; adoptive cell therapy; cancer; chimeric antigen receptor; gene transfer